Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a probiotic yogurt preparation containing the bacterium *Lactobacillus rhamnosus* (10^8 CFU/mL), specifically developed by the Centro Pediatrico Albina de Patino in Cochabamba, Bolivia. It was designed as a cost-effective alternative to lyophilized probiotic products for managing acute watery diarrhea in pediatric populations. The intervention functions as a live biotherapeutic, aiming to restore intestinal microflora balance and potentially enhance mucosal immune responses to combat enteric pathogens. In a randomized, double-blind, controlled clinical trial involving children aged 10 to 35 months, the preparation demonstrated therapeutic efficacy comparable to the standard probiotic *Saccharomyces boulardii* in reducing the duration and severity of diarrheal episodes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lactobacillus rhamnosus probiotic yogurt.